Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$165.45M$165.45M−1.7% vs Q2 2024 Net Income$22.50M$22.50M+13.0% vs Q2 2024 EPS Diluted$0.40$0.40+11.1% vs Q2 2024 Operating Income$12,141,000−46.2% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$58,080,000+63.3% Margins · derivedOperating margin7.3%−6.1 pt vs Q2 2024
Net margin13.6%+1.8 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 5, 2025 · 36 d after period end